Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias

24 Apr 2020

Abstract excerpt

There is no standard or widely effective treatment of patients with moderate aplastic anemia (MAA) or hypo-productive uni-lineage cytopenias (UC). Eltrombopag (EPAG), a small molecule thrombopoietin mimetic, has previously been shown to result in durable multi-lineage hematologic responses with low toxicity in patients with refractory severe aplastic anemia (SAA). Its safety and efficacy in MAA are unknown. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Hematopoietic Stem Cell Transplantation
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32330244
DOI: 10.1182/bloodadvances.2020001657

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopeniasPMID 32330244Read ↗

Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A StudySemantic proximity Read ↗

Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.Semantic proximity Read ↗

Treatment Overview of Fanconi Anemia and Other Inherited Bone Marrow Failure SyndromesSemantic proximity Read ↗

Prolonged Cytopenia with CAR-T Cell Therapy and Management RecommendationsSemantic proximity Read ↗

Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trialsSemantic proximity Read ↗

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Semantic proximity Read ↗

Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment.Semantic proximity Read ↗

Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.Semantic proximity Read ↗

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.Semantic proximity Read ↗

Distinctive and common features of moderate aplastic anaemia.Semantic proximity Read ↗

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trialSemantic proximity Read ↗

Acute promyelocytic leukemia (APL): remaining challenges towards a cure for allSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.